Anti-Atopic Dermatitis Activity of <i>Epi</i>-Oxyzoanthamine Isolated from Zoanthid
2023
Chieh-Chen Huang | Yuan-Hsin Lo | Yu-Jou Hsu | Yuan-Bin Cheng | Chia-Chi Kung | Cher-Wei Liang | Der-Chen Chang | Kang-Ling Wang | Chi-Feng Hung
Atopic dermatitis (AD, eczema) is a condition that causes dry, itchy, and inflamed skin and occurs most frequently in children but also affects adults. However, common clinical treatments provide limited relief and have some side effects. Therefore, there is a need to develop new effective therapies to treat AD. <i>Epi</i>-oxyzoanthamine is a small molecule alkaloid isolated from Formosan zoanthid. Relevant studies have shown that zoanthamine alkaloids have many pharmacological and biological activities, including anti-lymphangiogenic functions. However, there are no studies on the use of <i>epi</i>-oxyzoanthamine on the skin. In this paper, <i>epi</i>-oxyzoanthamine has been shown to have potential in the treatment of atopic dermatitis. Through in vitro studies, it was found that <i>epi</i>-oxyzoanthamine inhibited the expression of cytokines in TNF-α/IFN-γ-stimulated human keratinocyte (HaCaT) cells, and it reduced the phosphorylation of MAPK and the NF-κB signaling pathway. Atopic dermatitis-like skin inflammation was induced in a mouse model using 2,4-dinitrochlorobenzene (DNCB) in vivo. The results showed that <i>epi</i>-oxyzoanthamine significantly decreased skin barrier damage, scratching responses, and epidermal hyperplasia induced by DNCB. It significantly reduced transepidermal water loss (TEWL), erythema, ear thickness, and spleen weight, while also increasing surface skin hydration. These results indicate that <i>epi</i>-oxyzoanthamine from zoanthid has good potential as an alternative medicine for treating atopic dermatitis or other skin-related inflammatory diseases.
显示更多 [+] 显示较少 [-]